Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients

Abstract: Background:Currently, more than 37 million people are living with human immunodeficiency virus type 1. Reverse transcription (RT) is a main part in the life cycle of retroviruses which is   responsible for synthesis of DNA complementary to an RNA or DNA template.  Recently several inhibito...

Full description

Bibliographic Details
Main Authors: Behzad non Dehghani, Tayebeh Non Hashempour, Zahra non Mousavi, Javad non Moayedi, Zahra non Hasanshahi, Esmaeil non Rezaei, Farzaneh non Ghassabi
Format: Article
Language:Russian
Published: Sankt-Peterburg : NIIÈM imeni Pastera 2019-06-01
Series:Инфекция и иммунитет
Subjects:
Online Access:https://www.iimmun.ru/iimm/article/view/1383
_version_ 1797973108418674688
author Behzad non Dehghani
Tayebeh Non Hashempour
Zahra non Mousavi
Javad non Moayedi
Zahra non Hasanshahi
Esmaeil non Rezaei
Farzaneh non Ghassabi
author_facet Behzad non Dehghani
Tayebeh Non Hashempour
Zahra non Mousavi
Javad non Moayedi
Zahra non Hasanshahi
Esmaeil non Rezaei
Farzaneh non Ghassabi
author_sort Behzad non Dehghani
collection DOAJ
description Abstract: Background:Currently, more than 37 million people are living with human immunodeficiency virus type 1. Reverse transcription (RT) is a main part in the life cycle of retroviruses which is   responsible for synthesis of DNA complementary to an RNA or DNA template.  Recently several inhibitors have been introduced to target RT protein; however, drug resistance is one of the greatest challenges in the improvement of effective treatment for human immunodeficiency virus (HIV) infection. Here, we determined the resistance mutations in the RT gene in treatment failure patients and searched for the dominant subtype among them.  Methods:HIV viral load and a reverse transcriptase nested polymerase chain (RT-nested PCR) reactions were performed in 15 patients with treatment failure to amplify the RT gene. Drug resistance mutations, as well as the viral subtypes, were analyzed using by using several bioinformatics software and online tools. Results: The frequency of RT related drug-resistance mutations in patients was 33.3%, among which the major mutation consisted of 20% of all those occurring in codon 184. Moreover, the results showed 6.6% and 26.6% of patients were resistant to Non-Nucleoside RT Inhibitor (NNRTIs) and Nucleoside RT Inhibitors (NRTIs), respectively. In addition, the vast majority of samples (12 patients of 15) belonged to subtype CRF35-AD.Conclusions:The present study reports updates on the mutations related to RT resistance in Iranian HIV patients receiving treatment, show that 20% of the samples had a high-level of resistance to Lamivudine, and Emtricitabine which should be confirmed for further antiretroviral (AVR) regimens for HIV infected patients. Also, two new mutations related to resistance to Nevirapine, Doravirine, Zidovudine, and Stavudine were introduced in this investigation.The present results could be used as predictive information on the response to anti-RT, and also highlight the importance of considering the periodic monitoring of HIV resistance test in HIV infected patients.
first_indexed 2024-04-11T03:58:57Z
format Article
id doaj.art-d9c8d7f1f52e436aa92887c499f4512b
institution Directory Open Access Journal
issn 2220-7619
2313-7398
language Russian
last_indexed 2024-04-11T03:58:57Z
publishDate 2019-06-01
publisher Sankt-Peterburg : NIIÈM imeni Pastera
record_format Article
series Инфекция и иммунитет
spelling doaj.art-d9c8d7f1f52e436aa92887c499f4512b2023-01-02T00:08:16ZrusSankt-Peterburg : NIIÈM imeni PasteraИнфекция и иммунитет2220-76192313-73982019-06-01001010Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected PatientsBehzad non Dehghani0Tayebeh Non Hashempour1Zahra non Mousavi2Javad non Moayedi3Zahra non Hasanshahi4Esmaeil non Rezaei5Farzaneh non Ghassabi6Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranShiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, IranAbstract: Background:Currently, more than 37 million people are living with human immunodeficiency virus type 1. Reverse transcription (RT) is a main part in the life cycle of retroviruses which is   responsible for synthesis of DNA complementary to an RNA or DNA template.  Recently several inhibitors have been introduced to target RT protein; however, drug resistance is one of the greatest challenges in the improvement of effective treatment for human immunodeficiency virus (HIV) infection. Here, we determined the resistance mutations in the RT gene in treatment failure patients and searched for the dominant subtype among them.  Methods:HIV viral load and a reverse transcriptase nested polymerase chain (RT-nested PCR) reactions were performed in 15 patients with treatment failure to amplify the RT gene. Drug resistance mutations, as well as the viral subtypes, were analyzed using by using several bioinformatics software and online tools. Results: The frequency of RT related drug-resistance mutations in patients was 33.3%, among which the major mutation consisted of 20% of all those occurring in codon 184. Moreover, the results showed 6.6% and 26.6% of patients were resistant to Non-Nucleoside RT Inhibitor (NNRTIs) and Nucleoside RT Inhibitors (NRTIs), respectively. In addition, the vast majority of samples (12 patients of 15) belonged to subtype CRF35-AD.Conclusions:The present study reports updates on the mutations related to RT resistance in Iranian HIV patients receiving treatment, show that 20% of the samples had a high-level of resistance to Lamivudine, and Emtricitabine which should be confirmed for further antiretroviral (AVR) regimens for HIV infected patients. Also, two new mutations related to resistance to Nevirapine, Doravirine, Zidovudine, and Stavudine were introduced in this investigation.The present results could be used as predictive information on the response to anti-RT, and also highlight the importance of considering the periodic monitoring of HIV resistance test in HIV infected patients.https://www.iimmun.ru/iimm/article/view/1383hiv, rt, drug-resistance
spellingShingle Behzad non Dehghani
Tayebeh Non Hashempour
Zahra non Mousavi
Javad non Moayedi
Zahra non Hasanshahi
Esmaeil non Rezaei
Farzaneh non Ghassabi
Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
Инфекция и иммунитет
hiv, rt, drug-resistance
title Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
title_full Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
title_fullStr Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
title_full_unstemmed Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
title_short Investigation of Drug-resistance substitutions in HIV-1 RT Protein in Iranian HIV Infected Patients
title_sort investigation of drug resistance substitutions in hiv 1 rt protein in iranian hiv infected patients
topic hiv, rt, drug-resistance
url https://www.iimmun.ru/iimm/article/view/1383
work_keys_str_mv AT behzadnondehghani investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT tayebehnonhashempour investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT zahranonmousavi investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT javadnonmoayedi investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT zahranonhasanshahi investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT esmaeilnonrezaei investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients
AT farzanehnonghassabi investigationofdrugresistancesubstitutionsinhiv1rtproteininiranianhivinfectedpatients